---
document_datetime: 2023-09-21 19:01:45
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exalief-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: exalief-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0416613
conversion_datetime: 2025-12-24 15:49:24.597012
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3 Summary   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|------------------------------------------|
| IB/0025   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                | 10/02/2012                          | n/a                                         | SPC longer                               |
| WS/0120   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To add an alternative manufacturer of the active substance (eslicarbazepine acetate). B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions product | 15/12/2011                          | n/a no                                      |                                          |
| IA/0021/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished product - Minor                                                                                                                                                                                                                                                                                                                      | 27/10/2011                          | n/a                                         |                                          |

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

Telephone

+44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455

E-mail

info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<!-- image -->

Exalief Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures. 2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes. 3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0162   | change in the manufacturing process of an immediate release solid oral dosage form or oral solutions, B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SPC to add a number of adverse reactions resulting from CHMP assessment of an additional pooled analysis of phase III data. The PL has been updated accordingly. In addition, a cross- reference has been corrected in section 4.6 of the SmPC, and the contact details for the local representative in The Netherlands have been updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or product | 22/09/2011                          | 27/10/2011 no                               | SPC, PL                          | After CHMP assessment of the results obtained on an additional pooled analysis of the phase III data for eslicarbazepine acetate, the MAH has submitted a type II variation to add the adverse events 'irritability', 'chest pain' and 'urinary tract infection' to section 4.8 of the SPC as 'uncommon' events under the respective System Organ Class. longer authorised |
| IA/0020/G | pharmacovigilance data This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV, C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 13/04/2011                          | n/a                                         | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017/G | This was an application for a group of variations. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data, C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data                                                                                       | 21/10/2010                          | 29/11/2010 no                               | SPC, Annex II, PL                | Eslicarbazepine acetate is an antiepileptic drug which is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. At the time of the approval, the CHMP requested the MAH to investigate the possible drug- drug interaction with carbamazepine as a follow-up measure. In addition, the CHMP requested the investigation of the inducing effect of eslicarbazepine acetate on CYP3A4 in humans as a follow-up measure. In a drug-drug interaction study with carbamazepine, it was shown that concomitant administration of eslicarbazepine acetate 800 mg once daily and carbamazepine 400 mg twice daily resulted in an average decrease of approximately 30 %in exposure to the active metabolite eslicarbazepine most likely caused by an increase in metabolism. The dose of eslicarbazepine acetate may therefore need to be increased when used concomitantly with carbamazepine. Concomitant intake of eslicarbazepine acetate did not alter the pharmacokinetic profile of carbamazepine or its metabolite carbamazepine-epoxide. A study to examine the induction of CYP3A4 by eslicarbazepine acetate showed an average decrease of approximately 50 %in systemic exposure to simvastatin when co-administered with eslicarbazepine acetate 800 mg once daily. An increase of the simvastatin dose may therefore be required when used concomitantly with eslicarbazepine acetate. Section 4.5 of the SPC and section 2 of the PL have been updated with the new information, and the PI has been revised according to the current QRD template. longer authorised |
| IA/0019/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place, B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure, Medicinal product | 26/11/2010                          | n/a                                         |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------|
|         | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure, B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure, B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure, B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure, B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure, B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure, B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - | product                             | no                                          | longer                           | authorised |
| IB/0018 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28/10/2010                          | n/a                                         | SPC                              |            |
| IB/0016 | 17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/10/2009                          | n/a                                         |                                  |            |
| IA/0015 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 29/09/2009                          | n/a                                         |                                  |            |
| IB/0004 | 13_b_Change in test proc. for active substance - other changes (replacement/addition) Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 05/06/2009                          | n/a                                         |                                  |            |
| IB/0007 | 14_b_Change in manuf. of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 05/06/2009                          | n/a                                         |                                  |            |

<div style=\"page-break-after: always\"></div>

| No              | Scope                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary    |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------|
|                 | without Ph. Eur. certificate - new manufacturer                                                                                                                               |                                     |                                             |                                  |            |
| IB/0006         | 14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                                | 05/06/2009                          | n/a                                         |                                  | authorised |
| IB/0005         | 14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                                | 05/06/2009                          | n/a                                         |                                  |            |
| IB/0003         | 13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                         | 05/06/2009                          | n/a                                         | longer                           |            |
| IA/0001         | 13_a_Change in test proc. for active substance - minor change                                                                                                                 | 14/05/2009                          | n/a                                         |                                  |            |
| IA/0002         | 13_a_Change in test proc. for active substance - minor change                                                                                                                 | 14/05/2009                          | n/a                                         |                                  |            |
| IA/0008         | 38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                   | 14/05/2009                          | n/a no                                      |                                  |            |
| IA/0009         | 32_b_Change in batch size of the finished product - downscaling down to 10-fold                                                                                               | 14/05/2009                          | n/a                                         |                                  |            |
| IA/0014         | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms Medicinal product | 14/05/2009                          | n/a                                         |                                  |            |
| IA/0013         | 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                 | 14/05/2009                          | n/a                                         | Annex II, PL                     |            |
| IA/0010 IA/0011 | 38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                   | 14/05/2009                          | n/a                                         |                                  |            |
| IA/0010 IA/0011 | 38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                   | 14/05/2009                          | n/a                                         |                                  |            |

<div style=\"page-break-after: always\"></div>

<!-- image -->